J2 Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

J2 Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-928	Closed	-$413K	–	133
2025 Q2	$413K	Buy	928 +250	+37%	+$115K	0.33%	80
2025 Q1	$329K	Buy	678 +7	+1%	+$3.26K	0.3%	74
2024 Q4	$270K	Buy	+671	New	+$311K	0.25%	96
2023 Q3	$422K	Buy	1,213 +3	+0.2%	+$1.05K	0.53%	48
2023 Q2	$426K	Buy	1,210 +34	+3%	+$11.5K	0.51%	51
2023 Q1	$371K	Buy	+1,176	New	+$353K	0.57%	46
2022 Q3	–	Sell	-903	Closed	-$254K	–	103
2022 Q2	$254K	Sell	903 -1,012	-53%	-$271K	0.39%	64
2022 Q1	$500K	Buy	1,915 +41	+2%	+$9.73K	0.55%	31
2021 Q4	$412K	Buy	+1,874	New	+$364K	0.39%	43

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

J2 Capital Management's VRTX Position: Q3 2025 in Review

J2 Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 928 shares — an estimated $413K sold.

J2 Capital Management first reported a position in VRTX in Q4 2021 and held it in 9 quarters. The position peaked at $500K in Q1 2022. 1,523 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

J2 Capital Management reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
J2 Capital Management sold 928 Vertex Pharmaceuticals shares in Q3 2025, an estimated $413K.
J2 Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 9 quarters.
J2 Capital Management's Vertex Pharmaceuticals position peaked at $500K in Q1 2022.
1,523 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on J2 Capital Management's 13F filing for Q3 2025, filed 14 Oct 2025.